SynthesisPloS one2025
Chronic kidney disease among people living with HIV on TDF based regimen: A systematic review and meta-analysis.
Synthesis in PloS one, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed.
- Kidney abnormalities in young people living with HIV on dolutegravir-based regimens in Kampala, Uganda.AIDS research and therapy · 2026Article
- Clinical Outcomes of Tenofovir, Lamivudine, and Dolutegravir in Treatment-Naïve versus Treatment-Experienced HIV Patients: A Single-Center Retrospective Cohort Study in Indonesia.Infection & chemotherapy · 2026Article
- Kidney Dysfunction In Young People Living With HIV On Dolutegravir-Based Regimens In Kampala, Uganda.Research square · 2026Article
- Prevalence and incidence of non-communicable diseases among older adults living with HIV on antiretroviral therapy in Northern Haiti: A retrospective cohort study.PLOS global public health · 2026Article
- Evolution of kidney function after five years of follow-up in a large Spanish cohort of patients with HIV: risk factors for progression.BMC infectious diseases · 2025Observational
- Lipids and Body Mass Index in Antiretroviral-Experienced People With HIV on Doravirine-Based Treatments: A Comparison Between Dual or Triple Regimen Versus Bictegravir-Based Triple Regimen.AIDS research and treatment · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionChronic kidney disease is a major public health concern among people living with human immunodeficiency virus (PLWHIV) who are taking tenofovir disoproxil fumarate-based regimen. Despite the available evidence showing a high prevalence of CKD in this population, comprehensive pooled estimate of CKD among PLWHIV receiving TDF based regimen across the globe is lacking. Hence, the present systematic review aimed to provide a global pooled prevalence estimate of CKD.
methodWe conducted a systematic review of literatures published between January 2000 and May 2024. Articles and grey literature were searched from the following databases and search engine: PubMed, EMBASE, Scopus, Web of science, The Cumulative Index to Nursing and Allied Health Literature (CINHAL), and Google Scholar. We included eligible studies that report magnitude of CKD in TDF based regimen. We executed the pooled CKD, subgroup analysis, and funnel plot using random effect model. All statistical analysis including sensitivity analysis were made using Stata 17 software.
resultsSixty-nine studies with 88299 participants included in this meta-analysis. The pooled prevalence of CKD was 7% (95% CI:6-8). CD4 count less than 200 copies per milliliter, and being female were associated with CKD.
conclusionWe concluded that the magnitude of CKD across the globe is high in people living with HIV who have received TDF based regimen. Early identification of CKD by considering regular renal function monitoring, and risk factors especially low CD4 count, and female gender at birth are essential.
trial registrationThe protocol has been prospectively registered with PROSPERO ((CRD42020136813).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.